Related Experiment Video

Updated: May 20, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Evaluating the potential benefit of interferon treatment in multiple sclerosis

Tobias Derfuss, Ludwig Kappos

    JAMA
    |July 17, 2012
    PubMed
    Abstract

    No abstract available in PubMed .

    More Related Videos

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
    10:00

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

    Published on: March 24, 2015

    Related Experiment Videos

    Last Updated: May 20, 2026

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
    09:38

    Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

    Published on: September 12, 2016

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes
    10:00

    High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

    Published on: March 24, 2015

    Related Concept Videos

    Inhibitors of Viral Protein Synthesis01:30

    Inhibitors of Viral Protein Synthesis

    Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
    Multiple Sclerosis l: Introduction01:19

    Multiple Sclerosis l: Introduction

    Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...

    Articles linked to this work by shared authors, journal, and citation graph.

    Disability accrual in primary and secondary progressive multiple sclerosis.

    Journal of neurology, neurosurgery, and psychiatry·2023

    Effect of Previous Disease-Modifying Therapy on Treatment Effectiveness for Patients Treated With Ocrelizumab.

    Neurology(R) neuroimmunology & neuroinflammation·2023

    Assessment of cognitive performance in multiple sclerosis using smartphone-based training games: a feasibility study.

    Journal of neurology·2023

    An investigation of the association between focal damage and global network properties in cognitively impaired and cognitively preserved patients with multiple sclerosis.

    Frontiers in neuroscience·2023

    Personalized maps of T1 relaxometry abnormalities provide correlates of disability in multiple sclerosis patients.

    NeuroImage. Clinical·2023

    Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.

    Neurology(R) neuroimmunology & neuroinflammation·2023

    Arginine Therapy for Sickle Cell Disease Acute Pain Episodes: The STArT Randomized Clinical Trial.

    JAMA·2026

    Daily Zinc Supplementation for Infection Prevention in Children With Sickle Cell Anemia: The ZIPS-2 Randomized Clinical Trial.

    JAMA·2026

    Polycation chain length determines the in vivo mRNA delivery efficiency of block copolymer micelles.

    Biomaterials science·2026

    Driving Drugs Deeper: Force-Driven Microneedle Systems for Active Therapy and Their Road Towards Clinical Implementation.

    Small (Weinheim an der Bergstrasse, Germany)·2026

    Mumio Potentiates Temozolomide by Inducing Apoptosis and Ferroptosis in Glioblastoma Cells.

    Current pharmaceutical design·2026

    Current Targeted Nanoparticle Therapy for Alzheimer's Disease: Current Advances and Future Prospects.

    Current neurovascular research·2026

    Clinical Presentation, Diagnosis, Treatment, and Outcome of Heart Disease in Becker Muscular Dystrophy.

    Anatolian journal of cardiology·2026

    Clinical Pharmacology of Eplontersen, the First Approved GalNAc-Conjugated Antisense Oligonucleotide.

    Journal of clinical pharmacology·2026
    See all related articles
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    ABOUT JoVE
    OverviewLeadershipBlogJoVE Help Center
    AUTHORS
    Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
    LIBRARIANS
    TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
    RESEARCH
    JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
    EDUCATION
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
    Terms & Conditions of Use
    Privacy Policy
    Policies
    Jove
    Visualize
    Contact Us